Calico (company)
American research and development company
Calico LLC is an American research and development company founded in 2013 by Google and Arthur D. Levinson. The company focuses on the study of aging and associated diseases, with the aim of extending the human lifespan.
History[edit]
Calico was announced on September 18, 2013, by Larry Page, then CEO of Google, in a post on the official Google blog. The company was established as a subsidiary of Alphabet Inc., Google's parent company, and is headquartered in South San Francisco, California.
The name "Calico" is an abbreviation of "California Life Company." The company was founded with the mission to "harness advanced technologies to increase our understanding of the biology that controls lifespan."
Research Focus[edit]
Calico's research is primarily focused on understanding the biological mechanisms of aging and developing interventions to address age-related diseases. The company employs a multidisciplinary approach, combining genomics, bioinformatics, and molecular biology to explore the underlying causes of aging.
Aging and Longevity[edit]
Aging is a complex biological process that involves the gradual deterioration of cellular and molecular functions. Calico aims to identify the genetic and environmental factors that contribute to aging and to develop therapies that can slow down or reverse these processes.
[edit]
Calico's research also targets diseases that are prevalent in older populations, such as cancer, neurodegenerative diseases, and cardiovascular diseases. By understanding the common pathways that lead to these conditions, Calico hopes to develop treatments that can improve healthspan as well as lifespan.
Collaborations[edit]
Calico has established several partnerships with leading academic institutions and biotechnology companies to advance its research. Notable collaborations include partnerships with AbbVie, a global biopharmaceutical company, to develop and commercialize new therapies for age-related diseases.
Leadership[edit]
The company is led by Arthur D. Levinson, who serves as the CEO. Levinson is a prominent figure in the biotechnology industry, having previously served as the CEO of Genentech.
Facilities[edit]
Calico's research facilities are located in South San Francisco, where the company conducts its laboratory and clinical research. The facilities are equipped with state-of-the-art technology to support its scientific endeavors.
Related pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
